PsychonautWiki Archive

25B-NBOMe: Difference between revisions

← Older editNewer edit →
>8Brainzap8
updated legal status 25B
>Unity
m Grammatics
Line 3: Line 3:
{{SummarySheet}}
{{SummarySheet}}
{{SubstanceBox/25B-NBOMe}}
{{SubstanceBox/25B-NBOMe}}
'''25B-NBOMe''' (also known as '''Cimbi-36''', '''NBOMe-2C-B''' and '''2C-B-NBOMe''') is novel [[Psychoactive class::psychedelic]] substance of the [[chemical class::phenethylamine]] class. It is a member of the 25x-NBOMe series, a recently discovered group of potent psychedelic compounds derived from the [[2C-x]] family. The name 25B-NBOMe, which is short-hand for 2C-B-NBOMe, indicates it is a derivative of the phenethylamine psychedelic 2C-B.


'''25B-NBOMe''' (also known as '''Cimbi-36''', '''NBOMe-2C-B''' and '''2C-B-NBOMe''') is novel synthetic [[Psychoactive class::psychedelic]] substance of the [[chemical class::phenethylamine]] chemical class. It produces an array of visually-dominant and stimulating [[psychedelic]] effects when [[Routes of administration|administered]].  
25B-NBOMe was discovered in 2004 by Ralf Heim at the Free University of Berlin.<ref>Ralf Heim (February 28, 2010). [http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts."] (in German). diss.fu-berlin.de. Retrieved 2013-05-10.</ref> It acts as a potent partial agonist for the 5-HT<sub>2A</sub> receptor.<ref name="25BSAR">Hansen, M.; Phonekeo, K.; Paine, J. S.; Leth-Petersen, S.; Begtrup, M.; Bräuner-Osborne, H.; Kristensen, J. L. (2014). "Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists". ACS Chemical Neuroscience. 5 (3): 243–9. PMID 24397362. https://doi.org/10.1021/cn400216u</ref> It has been used in clinical trials with an evaluation dose for safety consideration to humans of only 1 microgram. Such a dose was determined to be only 1/300th the dose expected to be hallucinogenic to humans and that recreational use would greatly exceed doses determined to be safe to humans.<ref name="25BSAR" /> This substance had no history of human use before being sold online as a [[designer drug]] in 2010.{{citation needed}}


The name 25B-NBOMe, which short-hand for 2C-B-NBOMe, is a derivative of the phenethylamine psychedelic [[2C-B]]. It was discovered in 2004 by Ralf Heim at the Free University of Berlin.<ref>Ralf Heim (February 28, 2010). [http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts."] (in German). diss.fu-berlin.de. Retrieved 2013-05-10.</ref> It acts as a potent partial agonist for the 5-HT<sub>2A</sub> receptor.<ref name="25BSAR">Hansen, M.; Phonekeo, K.; Paine, J. S.; Leth-Petersen, S.; Begtrup, M.; Bräuner-Osborne, H.; Kristensen, J. L. (2014). "Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists". ACS Chemical Neuroscience. 5 (3): 243–9. PMID 24397362. https://doi.org/10.1021/cn400216u</ref> It has been used in clinical trials with an evaluation dose for safety consideration to humans of only 1 microgram. Such a dose was determined to be only 1/300th the dose expected to be hallucinogenic to humans and that recreational use would greatly exceed doses determined to be safe to humans.<ref name="25BSAR" />
[[Subjective effects]] include [[stimulation]], [[geometry|open and closed-eye visuals]], [[time distortion]], [[euphoria]], and [[ego loss]]. Anecdotal reports suggest 25B-NBOMe to be an active [[hallucinogen]] at a dose of as little as 250–500 µg, making it a similar potency to other phenethylamine derived [[hallucinogens]] such as [[Bromo-DragonFLY]].<ref>Bromo-Dragonfly Dosage by Erowid | https://erowid.org/chemicals/bromo_dragonfly/bromo_dragonfly_dose.shtml</ref> It is worth noting that compounds of the [[25x-NBOMe|NBOMe]] class are not [[oral|orally]] active and should therefore be taken [[sublingual|sublingually]] by placing them into one's mouth and allowing it to absorb over a period of 15-30 minutes.


Anecdotal reports from users suggest 25B-NBOMe to be an active [[hallucinogen]] at a dose of as little as 250–500 µg, making it a similar potency to other phenethylamine derived [[hallucinogens]] such as [[Bromo-DragonFLY]].<ref>Bromo-Dragonfly Dosage by Erowid | https://erowid.org/chemicals/bromo_dragonfly/bromo_dragonfly_dose.shtml</ref> It is worth noting that compounds of the [[25x-NBOMe|NBOMe]] class are not [[oral|orally]] active and should therefore be taken [[sublingual|sublingually]] by placing the substance into one's mouth and allowing it to slowly absorb over a period of 15-30 minutes.
Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25B-NBOMe in humans. Numerous members of the [[25x-NBOMe]] series have been associated with hospitalizations and deaths. Along with its highly sensitive dose-response and unpredictable effects, many reports also suggest that this substance may be overly difficult to use safely. Therefore it is highly advised to use [[harm reduction practices]] if using this substance.
 
This substance had no history of human use before being sold online as a [[designer drug]] in 2010.{{citation needed}} Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25B-NBOMe in humans, and numerous members of the [[25x-NBOMe]] series have been associated with hospitalizations and deaths. Along with its highly sensitive dose-response and unpredictable effects, many reports also suggest that this substance may be overly difficult to use safely. Therefore it is highly advised to approach this poorly understood, potentially deadly [[psychedelic]] substance with the proper amount of precaution and [[Responsible drug use#Hallucinogens|harm reduction practices]] if choosing to use it.


==Chemistry==
==Chemistry==
Retrieved from "http://psy.st/wiki/25B-NBOMe"